Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma.

哮喘是一种严重的慢性致残性疾病，影响全球超过 3 亿人。尽管过去很少有治疗哮喘的药物可用，但目前正在出现新的治疗选择，这似乎对某些患者亚组非常有效。因此，需要允许选择患者以进行精细和个性化治疗策略的生物标志物。最近，基于微阵列过敏原分子和源自最常见鼻病毒株的肽的血清学芯片测试已经开发出来，它可以区分两种最常见的哮喘形式，即过敏原和病毒引发的哮喘。从这个角度来看，